Atea Pharmaceuticals, Inc. (AVIR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $80.00K; Additional Paid in CapitalUSD $805.12M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-96.00K; Retained Earnings (Accumulated Deficit)USD $-600.94M.
- 2026-03-31: Common Stock, Value, IssuedUSD $80.00K; Additional Paid in CapitalUSD $801.74M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-97.00K; Retained Earnings (Accumulated Deficit)USD $-568.01M.
- 2025-12-31: Common Stock, Value, IssuedUSD $78.00K; Additional Paid in CapitalUSD $797.75M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $174.00K; Retained Earnings (Accumulated Deficit)USD $-522.57M.
- 2025-09-30: Common Stock, Value, IssuedUSD $78.00K; Additional Paid in CapitalUSD $793.17M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $238.00K; Retained Earnings (Accumulated Deficit)USD $-477.70M.
Atea Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $80.00K | $805.12M | $-96.00K | $-600.94M | $204.16M | 3 month · $3.38M | (m) |
| 2026-03-31 | $80.00K | $801.74M | $-97.00K | $-568.01M | $233.71M | 3 month · $3.73M | (m) |
| 2025-12-31 | $78.00K | $797.75M | $174.00K | $-522.57M | $275.43M | 12 month · $20.72M | (m) |
| 2025-09-30 | $78.00K | $793.17M | $238.00K | $-477.70M | $315.78M | 3 month · $4.52M | (m) |
| 2025-06-30 | $81.00K | $799.95M | $37.00K | $-435.65M | $364.42M | 3 month · $4.67M | (m) |
| 2025-03-31 | $85.00K | $809.37M | $118.00K | $-398.49M | $411.08M | 3 month · $6.95M | (m) |
| 2024-12-31 | $84.00K | $802.77M | $233.00K | $-364.22M | $438.87M | 12 month · $51.77M | (m) |
| 2024-09-30 | $84.00K | $788.47M | $641.00K | $-330.68M | $458.52M | 3 month · $12.16M | (m) |
| 2024-06-30 | $84.00K | $776.19M | $-280.00K | $-299.53M | $476.47M | 3 month · $12.72M | (m) |
| 2024-03-31 | $84.00K | $763.47M | $-181.00K | $-259.00M | $504.37M | 3 month · $12.59M | (m) |
| 2023-12-31 | $83.00K | $750.74M | $207.00K | $-195.84M | $555.19M | 12 month · $49.43M | (m) |
| 2023-09-30 | $83.00K | $738.58M | $-262.00K | $-156.67M | $581.73M | 3 month · $12.38M | (m) |
| 2023-06-30 | $83.00K | $726.11M | $-310.00K | $-123.53M | $602.35M | 3 month · $12.35M | (m) |
| 2023-03-31 | $83.00K | $713.75M | $-307.00K | $-95.35M | $618.18M | 3 month · $12.54M | (m) |
| 2022-12-31 | $83.00K | $701.05M | $-684.00K | $-59.88M | $640.57M | 12 month · $46.72M | (m) |
| 2022-09-30 | $83.00K | $689.41M | $-855.00K | $-25.45M | $663.19M | 3 month · $11.50M | (m) |
| 2022-06-30 | $83.00K | $677.76M | (m) | $-17.38M | $660.46M | 3 month · $11.91M | (m) |
| 2022-03-31 | $83.00K | $665.85M | (m) | $13.95M | $679.88M | 3 month · $11.66M | (m) |
| 2021-12-31 | $83.00K | $653.96M | (m) | $56.03M | $710.08M | 12 month · $39.62M | (m) |
| 2021-09-30 | $83.00K | $642.47M | (m) | $-61.10M | $581.45M | 3 month · $10.99M | (m) |
| 2021-06-30 | $83.00K | $630.69M | (m) | $-32.91M | $597.86M | 3 month · $10.01M | (m) |
| 2021-03-31 | $83.00K | $620.62M | (m) | $-34.45M | $586.26M | 3 month · $7.27M | (m) |
| 2020-12-31 | $82.00K | $612.88M | (m) | $-65.16M | $547.80M | 12 month · $6.80M | 12 month · $657.00K |
| 2020-09-30 | $10.00K | $9.29M | (m) | $-85.82M | $-76.51M | 3 month · $4.24M | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-63.13M | 3 month · $209.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-53.37M | 3 month · $189.00K | (m) |
| 2019-12-31 | $10.00K | $4.63M | (m) | $-54.21M | $-49.57M | 12 month · $624.00K | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | $-45.09M | 3 month · $157.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | $-41.62M | 3 month · $147.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | $-38.21M | 3 month · $146.00K | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $-36.16M | 12 month · $414.00K | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $-27.51M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |